<DOC>
	<DOCNO>NCT02673060</DOCNO>
	<brief_summary>This study evaluate MBC-11 ( conjugate bone-targeting vehicle ( etidronate ) cytostatic agent [ ara-C ] patient malignant tumor CIBD . This first use human .</brief_summary>
	<brief_title>A Trial MBC-11 Patients With CIBD</brief_title>
	<detailed_description>A standard `` 3+3 '' dose escalation design determine Maximum Tolerated Dose consecutive different dose level cohort recruitment . The follow dose level investigate : 0.5 mg/kg , 1.0 mg/kg , 2.5 mg/kg , 5.0 mg/kg , 10 mg/kgm 20 mg/kg . The study patient consist 14-days screening period , single dose administration MBC-11 follow 7-day safety monitor 2 cycle multiple use MBC-11 ( 28 day cycle , study drug administer Days1-5 ) . In case partial metabolic reaction/stable metabolic reaction therapy maybe prolong 4 cycle ( investigator sponsor consideration )</detailed_description>
	<criteria>Histologically confirm malignant tumor ( breast cancer , prostate cancer etc ) Bone metastasis , document radiograph , bone scan No available standard chemotherapy indication chemotherapy time screen Eastern Cooperative Oncology Group [ ECOG ] status 02 Adequate bone marrow function ( hemoglobin ≥ 9 g/dL without transfusion requirement , absolute neutrophil count ≥ 1500/mm3 , platelet ≥ 75,000/mm3 ) Adequate liver function ( bilirubin ≤ 2 x Upper Limit Normal [ ULN ] , Alanine aminotransferase [ ALT ] ≤ 2.5 x ULN ) . Adequate renal function ( creatinine ≤ 1.5 x ULN ) creatinine clearance ≥ 50 mL/min [ measure calculated nomogram ] ) . Systemic chemotherapy and/or investigational therapy within previous 4 week Fracture ≤ 6 month prior inclusion study Brain metastasis Serum calcium level &lt; 8.5 mg/dL ( &lt; 2.2 mmol/L )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>